TY - JOUR
T1 - Disturbed lipid and amino acid metabolisms in COVID-19 patients
AU - Masoodi, Mojgan
AU - Peschka, Manuela
AU - Schmiedel, Stefan
AU - Haddad, Munif
AU - Frye, Maike
AU - Maas, Coen
AU - Lohse, Ansgar
AU - Huber, Samuel
AU - Kirchhof, Paulus
AU - Nofer, Jerzy-Roch
AU - Renné, Thomas
N1 - Funding Information:
TR acknowledges the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) grants A11/SFB 877, B8/SFB 841 and P6/KFO 306. PK is partially supported by German Ministry of Education and Research (DZHK), and Leducq Foundation. PK receives further research support from European Union BigData@Heart (grant agreement EU IMI 116,074), British Heart Foundation (FS/13/43/30324; PG/17/30/32961 and PG/20/22/35093; AA/18/2/34218) and German Centre for Cardiovascular Research. The authors thank Dr. Sofia Tsouka for her assistance with pathway analysis.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/4
Y1 - 2022/4
N2 - The Coronavirus disease 2019 (COVID-19) pandemic is overwhelming the healthcare systems. Identification of systemic reactions underlying COVID-19 will lead to new biomarkers and therapeutic targets for monitoring and early intervention in this viral infection. We performed targeted metabolomics covering up to 630 metabolites within several key metabolic pathways in plasma samples of 20 hospitalized COVID-19 patients and 37 matched controls. Plasma metabolic signatures specifically differentiated severe COVID-19 from control patients. The identified metabolic signatures indicated distinct alterations in both lipid and amino acid metabolisms in COVID-19 compared to control patient plasma. Systems biology-based analyses identified sphingolipid, tryptophan, tyrosine, glutamine, arginine, and arachidonic acid metabolism as mostly impacted pathways in COVID-19 patients. Notably, gamma-aminobutyric acid (GABA) was significantly reduced in COVID-19 patients and GABA plasma levels allowed for stratification of COVID-19 patients with high sensitivity and specificity. The data reveal large metabolic disturbances in COVID-19 patients and suggest use of GABA as potential biomarker and therapeutic target for the infection.
AB - The Coronavirus disease 2019 (COVID-19) pandemic is overwhelming the healthcare systems. Identification of systemic reactions underlying COVID-19 will lead to new biomarkers and therapeutic targets for monitoring and early intervention in this viral infection. We performed targeted metabolomics covering up to 630 metabolites within several key metabolic pathways in plasma samples of 20 hospitalized COVID-19 patients and 37 matched controls. Plasma metabolic signatures specifically differentiated severe COVID-19 from control patients. The identified metabolic signatures indicated distinct alterations in both lipid and amino acid metabolisms in COVID-19 compared to control patient plasma. Systems biology-based analyses identified sphingolipid, tryptophan, tyrosine, glutamine, arginine, and arachidonic acid metabolism as mostly impacted pathways in COVID-19 patients. Notably, gamma-aminobutyric acid (GABA) was significantly reduced in COVID-19 patients and GABA plasma levels allowed for stratification of COVID-19 patients with high sensitivity and specificity. The data reveal large metabolic disturbances in COVID-19 patients and suggest use of GABA as potential biomarker and therapeutic target for the infection.
UR - http://www.scopus.com/inward/record.url?scp=85123504060&partnerID=8YFLogxK
U2 - 10.1007/s00109-022-02177-4
DO - 10.1007/s00109-022-02177-4
M3 - Article
C2 - 35064792
SN - 0946-2716
VL - 100
SP - 555
EP - 568
JO - Journal of Molecular Medicine
JF - Journal of Molecular Medicine
IS - 4
ER -